{"nct_id":"NCT04956692","title":"Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2024-11","start_date":"2021-08-05","start_date_type":"ACTUAL","primary_completion_date":"2023-04-04","primary_completion_date_type":"ACTUAL","completion_date":"2026-10-14","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["MRK"]}